{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T10:15:35Z","timestamp":1795169735211,"version":"4.10.3"},"reference-count":64,"publisher":"Informa UK Limited","issue":"9-10","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pharmacogenomics"],"published-print":{"date-parts":[[2026,10,3]]},"DOI":"10.1080\/14622416.2026.2746614","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:49:44Z","timestamp":1792162184000},"page":"631-640","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacogenetics in HIV therapy: a review of key biomarkers, regulatory annotations, and clinical dosing guidelines"],"prefix":"10.1080","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7989-6951","authenticated-orcid":false,"given":"Rita","family":"Nogueiras-\u00c1lvarez","sequence":"first","affiliation":[{"name":"Clinical Pharmacology. Galdakao-Usansolo University Hospital","place":["Bizkaia, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"e_1_3_5_3_1","unstructured":"Global HIV & AIDS statistics \u2014 fact sheet. Available from: https:\/\/www.unaids.org\/en\/resources\/fact-sheet"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1086\/501458"},{"key":"e_1_3_5_5_1","unstructured":"Clinical practice guidelines for HIV\/AIDS. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/14622416.2026.2658477"},{"key":"e_1_3_5_7_1","unstructured":"Abacavir - summary of product characteristics European Medicines Agency website. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ziagen-epar-product-information_en.pdf"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.355"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.10.021"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e3282f42224"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08158-8"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(02)07873-x"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706135"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1086\/529382"},{"key":"e_1_3_5_15_1","volume-title":"Chapter 6: infectious diseases pharmacogenomics, in pharmacogenomics: a primer for clinicians","author":"Lam JT","year":"2021","unstructured":"Lam JT. Chapter 6: infectious diseases pharmacogenomics, in pharmacogenomics: a primer for clinicians. McGraw Hill; 2021. https:\/\/accesspharmacy.mhmedical.com\/content.aspx?bookid=3020\u00a7ionid=254123357"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.38"},{"key":"e_1_3_5_17_1","unstructured":"The Royal Dutch Pharmacists Association - pharmacogenetics working group (DPWG) - August 2019 update. Available from: https:\/\/api.clinpgx.org\/v1\/download\/file\/attachment\/DPWG_August_2019.pdf"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/tan.70442"},{"key":"e_1_3_5_19_1","unstructured":"Atazanavir - summary of product characteristics European Medicines Agency website. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/atazanavir-krka-epar-product-information_en.pdf"},{"key":"e_1_3_5_20_1","unstructured":"Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services; [updated 2025 Sep 25]. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2011.618954"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2019.1617910"},{"key":"e_1_3_5_23_1","volume-title":"Medical genetics summaries [internet]","author":"Kane M","year":"2012","unstructured":"Kane M. Atazanavir therapy and UGT1A1 genotype. 2023 Oct 17. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical genetics summaries [internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK596252\/"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.269"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S107152"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2012.0233"},{"key":"e_1_3_5_27_1","unstructured":"The clinical pharmacogenetics implementation consortium. Gene-specific information tables for UGT1A1. Available from: https:\/\/files.cpicpgx.org\/data\/report\/current\/frequency\/UGT1A1_frequency_table.xlsx"},{"key":"e_1_3_5_28_1","unstructured":"Efavirenz\/Emtricitabine\/Tenofovir - summary of product characteristics European Medicines Agency website. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/efavirenz-emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_en.pdf"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/13596535211062396"},{"key":"e_1_3_5_30_1","unstructured":"HHS panel on antiretroviral guidelines for adults and adolescents\u2014A working group of the Office of AIDS Research advisory council (OARAC). Guidelines for the use of antiretroviral agents in adults and adolescents with HIVS. [Updated 2025 Sep 25]. In: ClinicalInfo.HIV.gov [Internet]. Rockville MD: US Department of Health and Human Services; 2002-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK586306\/"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.031393"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.1999.tb11662.x"},{"issue":"18","key":"e_1_3_5_33_1","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS clinical trials group study","volume":"18","author":"Haas DW","year":"2004","unstructured":"Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS clinical trials group study. AIDS. 2004;18(18):2391\u20132400.","journal-title":"AIDS"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1477"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101050-00011"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181f0634c"},{"key":"e_1_3_5_37_1","unstructured":"The clinical pharmacogenetics implementation consortium. Gene-specific information tables for CYP2B6. Available from: https:\/\/files.cpicpgx.org\/data\/report\/current\/frequency\/CYP2B6_frequency_table.xlsx"},{"key":"e_1_3_5_38_1","unstructured":"Dolutegravir - summary of product characteristics European Medicines Agency website. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tivicay-epar-product-information_en.pdf"},{"key":"e_1_3_5_39_1","unstructured":"Consolidated guidelines on HIV prevention testing treatment service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240031593"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.048918"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf098"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz558"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/14622416.2024.2441104"},{"key":"e_1_3_5_44_1","unstructured":"ClinPGx. DPWG: Dutch pharmacogenetics working group. Available from: https:\/\/www.clinpgx.org\/page\/dpwg"},{"key":"e_1_3_5_45_1","unstructured":"ClinPGx. What is CPIC? Available from: https:\/\/www.clinpgx.org\/cpic"},{"key":"e_1_3_5_46_1","unstructured":"The clinical pharmacogenetics implementation consortium guidelines. Available from: https:\/\/www.clinpgx.org\/cpic\/guidelines"},{"key":"e_1_3_5_47_1","unstructured":"The Dutch pharmacogenetics working group (DPWG) website. Available from: https:\/\/www.knmp.nl\/dossiers\/farmacogenetica"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2016.09.014"},{"key":"e_1_3_5_49_1","unstructured":"The Royal Dutch Pharmacists Association - pharmacogenetics working group (DPWG) - May 2023 update. Available from: https:\/\/api.clinpgx.org\/v1\/download\/file\/attachment\/pharmacogenetic_recommendation_text_20230801_downloaded_062425.pdf"},{"key":"e_1_3_5_50_1","unstructured":"The Royal Dutch Pharmacists Association - pharmacogenetics working group (DPWG) - June 2023 update. Available from: https:\/\/api.clinpgx.org\/v1\/download\/file\/attachment\/Farmacogenetica-Update-juni_2023.pdf"},{"key":"e_1_3_5_51_1","unstructured":"UK\u2019s HIV genomics database website. Available from: https:\/\/www.gov.uk\/guidance\/uk-hiv-genomics-database"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2350"},{"key":"e_1_3_5_53_1","unstructured":"U.S. Food and Drug Administration (FDA) website. Available from: https:\/\/www.fda.gov\/"},{"key":"e_1_3_5_54_1","unstructured":"European medicines agency (EMA) website. Available from: https:\/\/www.ema.europa.eu\/en\/homepage"},{"key":"e_1_3_5_55_1","unstructured":"Swiss agency for therapeutic products website. Available from: https:\/\/www.swissmedic.ch\/swissmedic\/en\/home.html"},{"key":"e_1_3_5_56_1","unstructured":"Health Canada (Sant\u00e9 Canada) website. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products.html"},{"key":"e_1_3_5_57_1","unstructured":"Pharmaceuticals and medical devices agency of Japan (PMDA) website. Available from: https:\/\/www.pmda.go.jp\/english\/"},{"key":"e_1_3_5_58_1","unstructured":"Drug label information and legend. Available from: https:\/\/www.clinpgx.org\/page\/drugLabelLegend#pgx-level"},{"key":"e_1_3_5_59_1","unstructured":"ClinPGx website. Available from: https:\/\/www.clinpgx.org\/drug\/PA449441\/labelAnnotation"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002160"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12267"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1177\/0268580919885292"},{"issue":"11","key":"e_1_3_5_63_1","first-page":"1483","article-title":"The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV","volume":"47","author":"Schackman BR","year":"2008","unstructured":"Schackman BR, Scott CA, Walensky RP, et al. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. Clin Infect Dis. 2008;47(11):1483\u20131492.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1186\/2047-783x-15-4-145"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11017-025-09723-4"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.66311\/3069-4310.02.01.01"}],"container-title":["Pharmacogenomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14622416.2026.2746614","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14622416.2026.2746614","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14622416.2026.2746614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T09:20:34Z","timestamp":1795166434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14622416.2026.2746614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":64,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2026,10,3]]}},"alternative-id":["10.1080\/14622416.2026.2746614"],"URL":"https:\/\/doi.org\/10.1080\/14622416.2026.2746614","relation":{},"ISSN":["1462-2416","1744-8042"],"issn-type":[{"value":"1462-2416","type":"print"},{"value":"1744-8042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgs20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgs20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-06-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}